Gaucher Disease Market Report - 2026

Gaucher Disease Market Report - 2026

  • August 2018 •
  • 145 pages •
  • Report ID: 5721288 •
  • Format: PDF
Gaucher Disease is a rare multi-systemic metabolic disorder which occurs due to the defective or insufficient activity of the glucocerebrosidase enzyme. The disease leads to the accumulation of substrate, glucocerebroside in tissue macrophages, and damage to hematological, visceral, and bone systems. Painless splenomegaly, anemia, thrombocytopenia, chronic fatigue, hepatomegaly, bone pain, pathologic fractures, and others are the most frequent manifestations of Gaucher Disease.

Gaucher Disease is classified as Gaucher Disease Type 1, Gaucher Disease Type 2 and Gaucher Disease Type 3 based on clinical subtypes. The United States accounts for the highest prevalence of the disease with 8,000 cases, followed by EU5 (the United Kingdom, Germany, France, and Italy) and Japan. Gaucher Disease Type 1 is more prevalent in comparison to Gaucher Disease Type 2 and Gaucher Disease Type 3.
The market size of Gaucher Disease in seven major markets is expected to reach $1,456 million in 2026. The United States accounts for the highest market share in comparison to EU5 (United Kingdom, Germany, France, and Italy) and Japan, as the US has the highest prevalence of cases, increasing research activities, and improved healthcare resources. Among European countries, Germany accounts for the highest market share, followed by France.

Elelyso (taliglucerase alfa), Vpriv (velaglucerase alfa) and Cerezyme (imiglucerase) are the approved Enzyme Replacement Therapies, whereas miglustat (Zavesca) and eliglustat (Cerdelga) are the approved Substrate Reduction Therapies for the treatment of Gaucher Disease Type 1. The use of Enzyme Replacement Therapies has resulted in improved anemia and low platelet counts in patients, as well as reduced enlargement of the liver and spleen. Substrate Reduction Therapy provides a consistent dosage to patients in comparison to enzyme replacement therapy.

Major players such as Belrose Pharma, Sanofi-Genzyme, AVROBIO, Inc, Lixte Biotechnology Holdings, Inc., Orphazyme A.S and other companies are involved in developing therapies for the treatment of Gaucher Disease. The launch of emerging therapies such as Arimoclomol (2024) and Venglustat (2026) is expected to fuel market growth. An increase in the number of collaborations and agreements between companies and universities, improved diagnosis, and increasing awareness regarding Gaucher Disease will have a positive impact on the market during the forecasted period.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.